PGI2
Phase 1Small molecule
PGI2 is one of 33 small molecule programs targeting Headache. It is currently in Phase 1.
2
Indications
2
Total Trials
0
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
154 competitors in Pulmonary Hypertension
#DrugCompanyPhaseTrials
1Reata
BiogenPhase 3
Diamox
TevaPhase 3
Crestor
AstraZenecaPhase 3
Lexapro
AbbViePhase 3
Zesly
MMezzion Pharma Co. Ltd
Phase 3
Accrufer
SShield Therapeutics
Phase 3
Distilled Water
GSKPhase 3
Diluent
SanofiPhase 3
Remodulin
United TherapeuticsPhase 3
Iloprost Inhalation
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Pulmonary Hypertension1 trial
PGI2 Versus Nitroglycerine for Management of Pulmonary Hypertension After Valve Surgeries
Unknown status·—·Phase 1·NCT04594629·120 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PGI2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- DDanish Headache Center